Clinical Review of Treatment Options for Select Nonrnotor Symptoms of Parkinson's Disease

被引:49
|
作者
Wood, Lindy D. [1 ]
Neumiller, Joshua J. [1 ]
Setter, Stephen M. [1 ]
Dobbins, Erin K. [2 ]
机构
[1] Washington State Univ, Coll Pharm, Dept Pharmacotherapy, Elder Serv, Spokane, WA 99217 USA
[2] Family Home Care & Hospice, Liberty Lake, WA USA
关键词
Parkinson's disease; nonmotor; pharmacologic management; nonpharmacologic management; SLEEP BEHAVIOR DISORDER; DRUG-INDUCED PSYCHOSIS; RESTLESS LEGS SYNDROME; EXCESSIVE DAYTIME SLEEPINESS; PLACEBO-CONTROLLED TRIAL; MULTIPLE SYSTEM ATROPHY; COGNITIVE IMPAIRMENT; FOLLOW-UP; REM-SLEEP; SWALLOWING DISORDERS;
D O I
10.1016/j.amjopharm.2010.08.002
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background: Parkinson's disease (PD) is associated with a host of nonmotor symptoms, including psychosis, cognitive impairment, depression, sleep disturbance, swallowing disorders, gastrointestinal symptoms, and autonomic dysfunction. The nonmotor symptoms of PD have the potential to be more debilitating than the motor features of the disorder. Objective: The aim of this article was to review treatment options for the nonmotor manifestations of PD, including pharmacologic and nonpharmacologic interventions. Methods: The PubMed and MEDLINE databases were searched for articles published in English between January 1966 and April 2010, using the terms Parkinson's disease, nonmotor, psychosis, hallucination, antipsychotic, cognitive impairment, dementia, depression, sleep disturbance, sleepiness, REM (rapid eye movement) sleep behavior disorder, dysphagia, swallowing disorder, sialorrhea, gastrointestinal, constipation, autonomic dysfunction, orthostatic hypotension, gastroparesis, erectile dysfunction, sexual dysfunction, and urinary dysfunction. Articles were selected for review if they were randomized controlled trials (RCTs), meta-analyses, or evidence-based reviews of treatment of patients with PD, and/or expert opinion regarding the treatment of nonmotor symptoms of PD. Results: A total of 148 articles, including RCTs, meta-analyses, and evidence-based reviews, were included in this review. The treatment of hallucinations or psychosis in PD should include a stepwise reduction in medications for motor symptoms, followed by the use of quetiapine or clozapine. Dementia may be treated with acetylcholinesterase inhibitors. Evidence is lacking concerning the optimal pharmacologic treatment for depression in PD, with expert opinions indicating selective serotonin reuptake inhibitors as the antidepressants of choice. However, the largest study to date found nortriptyline therapy to be efficacious compared with placebo, whereas paroxetine controlled release was not. A variety of sleep disturbances may plague a person with PD, and treatment must be individualized to the patient's specific sleep disturbance pattern and contributing factors. Swallowing disorders may lead to aspiration and pneumonia, and patients with dysphagia should be referred to a speech therapist for further evaluation and treatment. Orthostasis may be treated with nonpharmacologic interventions as well as pharmacologic treatments (eg, fludrocortisone, midodrine, indomethacin). Other autonomic symptoms are managed in a manner similar to that in patients without PD, although careful attention must be aimed at avoiding dopamine-blocking therapies in the treatment of gastrointestinal dysfunction and gastroparesis. Conclusions: Various pharmacologic and nonpharmacologic strategies are available for the management of the nonmotor symptoms of PD. The challenges associated with nonmotor symptoms must not be forgotten in light of the motor symptoms of PD, and treatment of nonmotor symptoms should be encouraged. (Am J Geriatr Pharmacother. 2010;8:294-315) (C) 2010 Excerpta Medica Inc.
引用
收藏
页码:294 / 315
页数:22
相关论文
共 50 条
  • [1] Clinical Review and Treatment of Select Adverse Effects of Dopamine Receptor Agonists in Parkinson's Disease
    Wood, Lindy D.
    DRUGS & AGING, 2010, 27 (04) : 295 - 310
  • [2] Mastering nocturnal jigsaws in Parkinson's disease: a dusk-to-dawn review of night-time symptoms
    Bhidayasiri, Roongroj
    Sringean, Jirada
    Trenkwalder, Claudia
    JOURNAL OF NEURAL TRANSMISSION, 2020, 127 (05) : 763 - 777
  • [3] Treatment Options for Sleep Dysfunction in Parkinson's Disease
    Thenganatt, Mary Ann
    Frucht, Steven J.
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2011, 13 (05) : 473 - 487
  • [4] A clinical overview of non-motor symptoms in Parkinson's disease
    Modugno, N.
    Lena, F.
    Di Biasio, F.
    Cerrone, G.
    Ruggieri, S.
    Fornai, F.
    ARCHIVES ITALIENNES DE BIOLOGIE, 2013, 151 (04): : 148 - 168
  • [5] The clinical symptoms of Parkinson's disease
    Sveinbjornsdottir, Sigurlaug
    JOURNAL OF NEUROCHEMISTRY, 2016, 139 : 318 - 324
  • [6] Sensory Symptoms in Parkinson's Disease: Clinical Features, Pathophysiology, and Treatment
    Zhu, Mingxin
    Li, Man
    Ye, Dawei
    Jiang, Wei
    Lei, Ting
    Shu, Kai
    JOURNAL OF NEUROSCIENCE RESEARCH, 2016, 94 (08) : 685 - 692
  • [7] Therapeutic options for nocturnal problems in Parkinson's disease and atypical parkinsonian disorders
    Klingelhoefer, Lisa
    Sokolov, Elisaveta
    Chaudhuri, K. Ray
    JOURNAL OF NEURAL TRANSMISSION, 2014, 121 : S25 - S31
  • [8] Treatment options for Parkinson's disease
    Tintner, R
    Jankovic, J
    CURRENT OPINION IN NEUROLOGY, 2002, 15 (04) : 467 - 476
  • [9] Treatment Options for Motor and Non-Motor Symptoms of Parkinson's Disease
    Church, Frank C.
    BIOMOLECULES, 2021, 11 (04)
  • [10] Treatment strategies for nonmotor manifestations of Parkinson's disease
    Reichmann, Heinz
    Ziemssen, Tjalf
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (05) : 773 - 784